Clinical Trial Update: Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing the safety of the PENTAXIM pentavalent vaccine given as a three-dose primary series at 2, 3, and 4 months of age in Chinese inf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Pentaxim

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 4 | Status: COMPLETED